UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 206

Sortiert nach

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development

Clinical cancer research, 2004-06, Vol.10 (11), p.3885-3896

2004

Link zum Volltext

Verfügbarkeit prüfen

Angiogenesis as a therapeutic target

Nature, 2005-12, Vol.438 (7070), p.967-974

2005

Link zum Volltext

Verfügbarkeit prüfen

The anti-angiogenic basis of metronomic chemotherapy

Nature reviews. Cancer, 2004-06, Vol.4 (6), p.423-436

2004

Link zum Volltext

Verfügbarkeit prüfen

Tumor angiogenesis: past, present and the near future

Carcinogenesis (New York), 2000-03, Vol.21 (3), p.505-515

KERBEL, R. S

2000

Link zum Volltext

Verfügbarkeit prüfen

Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived-But They Can Be Improved

Cancer biology & therapy, 2003-07, Vol.2 (4 Suppl 1), p.133-138

Kerbel, Robert S.

2003

Link zum Volltext

Verfügbarkeit prüfen

Thrombospondin 1, a Mediator of the Antiangiogenic Effects of Low-Dose Metronomic Chemotherapy

Proceedings of the National Academy of Sciences - PNAS, 2003-10, Vol.100 (22), p.12917-12922

2003

Link zum Volltext

Verfügbarkeit prüfen

Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells

Cancer research (Chicago, Ill.), 2003-08, Vol.63 (15), p.4342-4346

2003

Link zum Volltext

Verfügbarkeit prüfen

Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs

Cancer research (Chicago, Ill.), 2002-12, Vol.62 (23), p.6938-6943

2002

Link zum Volltext

Verfügbarkeit prüfen

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity

Blood, 2005-11, Vol.106 (9), p.3058-3061

2005

Link zum Volltext

Verfügbarkeit prüfen

Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy

Cancer research (Chicago, Ill.), 2006-04, Vol.66 (7), p.3386-3391

2006

Link zum Volltext

Verfügbarkeit prüfen

A cancer therapy resistant to resistance

Nature (London), 1997-11, Vol.390 (6658), p.335-336

Kerbel, Robert S

1997

Link zum Volltext

Verfügbarkeit prüfen

Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis

Cancer cell, 2005, Vol.7 (1), p.101-111

2005

Link zum Volltext

Verfügbarkeit prüfen

A Role for Survivin in Chemoresistance of Endothelial Cells Mediated by VEGF

Proceedings of the National Academy of Sciences - PNAS, 2002-04, Vol.99 (7), p.4349-4354

2002

Link zum Volltext

Verfügbarkeit prüfen

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis

Cancer research (Chicago, Ill.), 2001-07, Vol.61 (13), p.5090-5101

2001

Link zum Volltext

Verfügbarkeit prüfen

Clinical trials of antiangiogenic drugs : Opportunities, problems, and assessment of initial results

Journal of clinical oncology, 2001-09, Vol.19 (18), p.45s-51s

KERBEL, Robert S

2001

Link zum Volltext

Verfügbarkeit prüfen

Effect of p53 Status on Tumor Response to Antiangiogenic Therapy

Science (American Association for the Advancement of Science), 2002-02, Vol.295 (5559), p.1526-1528

2002

Link zum Volltext

Verfügbarkeit prüfen

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

The Journal of clinical investigation, 2000-04, Vol.105 (8), p.R15-R24

2000

Link zum Volltext

Verfügbarkeit prüfen

Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed

Cancer cell, 2005-10, Vol.8 (4), p.269-271

Kerbel, Robert S.

2005

Link zum Volltext

Verfügbarkeit prüfen

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors

The American journal of pathology, 1997-12, Vol.151 (6), p.1523-1530

1997

Link zum Volltext

Verfügbarkeit prüfen

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water

Cancer research (Chicago, Ill.), 2002-05, Vol.62 (10), p.2731-2735

2002

Link zum Volltext

Verfügbarkeit prüfen

Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia

Cancer research (Chicago, Ill.), 2006-04, Vol.66 (7), p.3639-3648

2006

Link zum Volltext

Verfügbarkeit prüfen

Differences in Therapeutic Indexes of Combination Metronomic Chemotherapy and an Anti-VEGFR-2 Antibody in Multidrug-resistant Human Breast Cancer Xenografts

Clinical cancer research, 2002-01, Vol.8 (1), p.221-232

2002

Link zum Volltext

Verfügbarkeit prüfen

Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation

Annals of oncology, 2005-08, Vol.16 (8), p.1243-1252

2005

Link zum Volltext

Verfügbarkeit prüfen

Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic

Annals of oncology, 2002-01, Vol.13 (1), p.12-15

2002

Link zum Volltext

Verfügbarkeit prüfen

Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts

Clinical cancer research, 2006-02, Vol.12 (3), p.904-916

2006

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 206

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(197)
Mit Volltextzugriff
(191)

Publikationsform

Artikel
(204)
Tagungsberichte
(2)

Sprache

Englisch
(206)
Japanisch
(29)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development

Angiogenesis as a therapeutic target

The anti-angiogenic basis of metronomic chemotherapy

Tumor angiogenesis: past, present and the near future

Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived-But They Can Be Improved

Thrombospondin 1, a Mediator of the Antiangiogenic Effects of Low-Dose Metronomic Chemotherapy

Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells

Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs

Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity

Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy

A cancer therapy resistant to resistance

Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: Implications for cellular surrogate marker analysis of antiangiogenesis

A Role for Survivin in Chemoresistance of Endothelial Cells Mediated by VEGF

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis

Clinical trials of antiangiogenic drugs : Opportunities, problems, and assessment of initial results

Effect of p53 Status on Tumor Response to Antiangiogenic Therapy

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed

Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors

Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water

Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia

Differences in Therapeutic Indexes of Combination Metronomic Chemotherapy and an Anti-VEGFR-2 Antibody in Multidrug-resistant Human Breast Cancer Xenografts

Cyclophosphamide-methotrexate ‘metronomic’ chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation

Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic

Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts

Suchergebnisse filtern